416 related articles for article (PubMed ID: 27893699)
21. Acute Cerebellar Ataxia Induced by Nivolumab.
Kawamura R; Nagata E; Mukai M; Ohnuki Y; Matsuzaki T; Ohiwa K; Nakagawa T; Kohno M; Masuda R; Iwazaki M; Takizawa S
Intern Med; 2017; 56(24):3357-3359. PubMed ID: 29249765
[TBL] [Abstract][Full Text] [Related]
22. [Psoriasis and Psoriatic Arthritis Induced by Nivolumab in a Patient with Advanced Non-Small-Cell Lung Cancer].
Sugiura Y; Fujimoto H; Yamamoto M; Nomura H; Hashizume T; Kawai O; Araki N; Kawakami K; Sueki H; Fusegawa H; Ohkubo Y; Nemoto E
Gan To Kagaku Ryoho; 2017 Sep; 44(9):787-789. PubMed ID: 28912410
[TBL] [Abstract][Full Text] [Related]
23. A case of autoimmune haemolytic anaemia after 39 cycles of nivolumab.
Shaikh H; Daboul N; Albrethsen M; Fazal S
BMJ Case Rep; 2018 Apr; 2018():. PubMed ID: 29669775
[TBL] [Abstract][Full Text] [Related]
24. Nivolumab: a review in advanced squamous non-small cell lung cancer.
Keating GM
Drugs; 2015 Nov; 75(16):1925-34. PubMed ID: 26514815
[TBL] [Abstract][Full Text] [Related]
25. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
[TBL] [Abstract][Full Text] [Related]
26. Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression.
Tanizaki J; Hayashi H; Kimura M; Tanaka K; Takeda M; Shimizu S; Ito A; Nakagawa K
Lung Cancer; 2016 Dec; 102():44-48. PubMed ID: 27987588
[TBL] [Abstract][Full Text] [Related]
27. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
Rizvi NA; Mazières J; Planchard D; Stinchcombe TE; Dy GK; Antonia SJ; Horn L; Lena H; Minenza E; Mennecier B; Otterson GA; Campos LT; Gandara DR; Levy BP; Nair SG; Zalcman G; Wolf J; Souquet PJ; Baldini E; Cappuzzo F; Chouaid C; Dowlati A; Sanborn R; Lopez-Chavez A; Grohe C; Huber RM; Harbison CT; Baudelet C; Lestini BJ; Ramalingam SS
Lancet Oncol; 2015 Mar; 16(3):257-65. PubMed ID: 25704439
[TBL] [Abstract][Full Text] [Related]
28. Dramatic Antitumor Activity of Nivolumab in Advanced HER2-Positive Lung Cancer.
Catania C; Passaro A; Rocco EG; Spitaleri G; Barberis M; Noberasco C; Signore ED; Travaini L; de Marinis F
Clin Lung Cancer; 2016 Sep; 17(5):e179-e183. PubMed ID: 27349506
[No Abstract] [Full Text] [Related]
29. Immune-related intestinal pseudo-obstruction associated with nivolumab treatment in a lung cancer patient.
Fragulidis G; Pantiora E; Michalaki V; Kontis E; Primetis E; Vezakis A; Polydorou A
J Oncol Pharm Pract; 2019 Mar; 25(2):487-491. PubMed ID: 29067858
[TBL] [Abstract][Full Text] [Related]
30. Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
Gettinger S; Rizvi NA; Chow LQ; Borghaei H; Brahmer J; Ready N; Gerber DE; Shepherd FA; Antonia S; Goldman JW; Juergens RA; Laurie SA; Nathan FE; Shen Y; Harbison CT; Hellmann MD
J Clin Oncol; 2016 Sep; 34(25):2980-7. PubMed ID: 27354485
[TBL] [Abstract][Full Text] [Related]
31. Recurrent Episodes of Nivolumab-Induced Pneumonitis after Nivolumab Discontinuation and the Time Course of Carcinoembryonic Antigen Levels: A Case of a 58-Year-Old Woman with Non-Small Cell Lung Cancer.
de Jong C; Peters BJM; Schramel FMNH
Chemotherapy; 2018; 63(5):272-277. PubMed ID: 30572331
[TBL] [Abstract][Full Text] [Related]
32. Resolution of Infliximab-Refractory Nivolumab-Induced Acute Severe Enterocolitis After Cyclosporine Treatment in a Patient with Non-Small Cell Lung Cancer.
Iyoda T; Kurita N; Takada A; Watanabe H; Ando M
Am J Case Rep; 2018 Mar; 19():360-364. PubMed ID: 29581417
[TBL] [Abstract][Full Text] [Related]
33. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Brahmer J; Reckamp KL; Baas P; Crinò L; Eberhardt WE; Poddubskaya E; Antonia S; Pluzanski A; Vokes EE; Holgado E; Waterhouse D; Ready N; Gainor J; Arén Frontera O; Havel L; Steins M; Garassino MC; Aerts JG; Domine M; Paz-Ares L; Reck M; Baudelet C; Harbison CT; Lestini B; Spigel DR
N Engl J Med; 2015 Jul; 373(2):123-35. PubMed ID: 26028407
[TBL] [Abstract][Full Text] [Related]
34. Isolated Adrenocorticotropin Deficiency due to Nivolumab-induced Hypophysitis in a Patient with Advanced Lung Adenocarcinoma: A Case Report and Literature Review.
Ohara N; Ohashi K; Fujisaki T; Oda C; Ikeda Y; Yoneoka Y; Hashimoto T; Hasegawa G; Suzuki K; Takada T
Intern Med; 2018 Feb; 57(4):527-535. PubMed ID: 29151505
[TBL] [Abstract][Full Text] [Related]
35. The safety of nivolumab for the treatment of advanced non-small cell lung cancer.
Metro G; Ricciuti B; Brambilla M; Baglivo S; Soli I; Minenza E; Leonardi GC; D'arpino A; Colabrese D; Tazza M; Zicari D; Minotti V; Chiari R
Expert Opin Drug Saf; 2017 Jan; 16(1):101-109. PubMed ID: 27910704
[TBL] [Abstract][Full Text] [Related]
36. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
Yamauchi I; Sakane Y; Fukuda Y; Fujii T; Taura D; Hirata M; Hirota K; Ueda Y; Kanai Y; Yamashita Y; Kondo E; Sone M; Yasoda A; Inagaki N
Thyroid; 2017 Jul; 27(7):894-901. PubMed ID: 28537531
[TBL] [Abstract][Full Text] [Related]
37. Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer.
Kato T; Masuda N; Nakanishi Y; Takahashi M; Hida T; Sakai H; Atagi S; Fujita S; Tanaka H; Takeda K; Satouchi M; Namba Y; Tamura T
Lung Cancer; 2017 Feb; 104():111-118. PubMed ID: 28212992
[TBL] [Abstract][Full Text] [Related]
38. Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report.
Narumi Y; Yoshida R; Minami Y; Yamamoto Y; Takeguchi S; Kano K; Takahashi K; Saito T; Sawada J; Terui H; Katayama T; Sasaki T; Ohsaki Y
BMC Cancer; 2018 Jan; 18(1):95. PubMed ID: 29361915
[TBL] [Abstract][Full Text] [Related]
39. Understanding immunotherapy for the treatment of non-small cell lung cancer.
Thomas R
Br J Nurs; 2016 Sep; 25(16):S12-7. PubMed ID: 27615536
[TBL] [Abstract][Full Text] [Related]
40. Positive Conversion of PD-L1 Expression After Treatments with Chemotherapy and Nivolumab.
Haratake N; Toyokawa G; Tagawa T; Kozuma Y; Matsubara T; Takamori S; Akamine T; Yamada Y; Oda Y; Maehara Y
Anticancer Res; 2017 Oct; 37(10):5713-5717. PubMed ID: 28982891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
